Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions: Original article: Laboratory investigation

International Journal of Urology

Volumn 17, Issue 3, 2010, Pages 281-285

  Suzuki, Yasutomo ^a   Kondo, Yukihiro ^a   Hara, Shuntaro ^b   Kimata, Ryouji ^a   Nishimura, Taiji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Androgen response; Geldanamycin; Hypoxic conditions; LNCaP

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL HYPOXIA; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DNA RESPONSIVE ELEMENT; HORMONE RESPONSE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REPORTER GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANDROGENS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; CELL DIVISION; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LACTAMS, MACROCYCLIC; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION;

EID: 77749237278     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02450.x     Document Type: Article

References (22)

1. Crawford ED, Eisenberger MA, McLeod DG. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989 321 : 419 424.
2. Dales JP, Garcia S, Meunier-Carpentier S et al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 2005 116 : 734 739.
3. Theodoropoulos VE, Lazaris AC, Kastriotis I et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 2005 95 : 425 431.
4. Giatromanolaki A, Koukourakis MI, Sowter HM et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin. Cancer Res. 2004 10 : 5566 5571.
5. Movsas B, Chapman JD, Greenberg RE et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 2000 89 : 2018 2024.
6. Vanaja DK, Mitchell SH, Toft DO, Young CY. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002 7 : 55 64.
7. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 2002 277 : 29936 29944.
8. Whitesell L, Shfrin SD, Schwab G, Neckers LM. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 1992 52 : 1721 1728.
9. Yamabe Y, Hoshino A, Imura N, Suzuki T, Himeno S. Enhancement of androgen-dependent transcription and cell proliferation by tributyltin and triphenyltin in human prostate cancer cells. Toxicol. Appl. Pharmacol. 2000 169 : 177 184.
10. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem. Biophys. Res. Commun. 2001 287 : 808 813.
11. 2 study. Am. J. Clin. Oncol. 2001 24 : 458 461.
12. Cvetkovic D, Movsas B, Dicker AP et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001 57 : 821 825.
13. Karl TB, Helen OM, Andrea D et al. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int. J. Cancer 2008 123 : 760 768.
14. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase b in prostate cancer cells. Clin. Cancer Res. 2003 9 : 2416 2425.
15. Zagzag D, Nomura M, Friedlander DR et al. Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J. Cell. Physiol. 2003 196 : 394 402.
16. Mabjeesh NJ, Post DE, Willard MT et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002 62 : 2478 2482.
17. Katschinski DM, Le L, Heinrich D et al. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J. Biol. Chem. 2002 277 : 9262 9267.
18. Thomas SA, Brown IL, Hollins GW et al. Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br. J. Urol. 1996 77 : 367 372.
19. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001 58 : 289 294.
20. Soo YP, Yun JK, Allen CG et al. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res. 2006 66 : 5121 5129.
21. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004 351 : 1513 1520.
22. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin. Oncol. 2003 30 : 709 716.